Cargando…
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome
OBJECTIVES: To evaluate the interferon (IFN) biomarkers sialic acid binding Ig like lectin 1 (SIGLEC1, CD169) and IFN-γ-inducible protein-10 (IP-10) in patients with primary Sjögren's syndrome (pSS). METHODS: 31 patients fulfilling the American-European criteria for pSS were included. Disease a...
Autores principales: | Rose, Thomas, Szelinski, Franziska, Lisney, Anna, Reiter, Karin, Fleischer, Sarah J, Burmester, Gerd R, Radbruch, Andreas, Hiepe, Falk, Grützkau, Andreas, Biesen, Robert, Dörner, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237743/ https://www.ncbi.nlm.nih.gov/pubmed/28123773 http://dx.doi.org/10.1136/rmdopen-2016-000292 |
Ejemplares similares
-
Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019) -
Cigarette smoking patterns preceding primary Sjögren’s syndrome
por: Mofors, Johannes, et al.
Publicado: (2020) -
Sjögren’s and non-Sjögren’s sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature
por: Pucino, Valentina, et al.
Publicado: (2022) -
Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022) -
Efficacy of daratumumab in refractory primary Sjögren disease
por: Nocturne, Gaetane, et al.
Publicado: (2023)